Skip to main content
Erschienen in: European Radiology 5/2009

01.05.2009 | Hepatobiliary-Pancreas

Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation

Erschienen in: European Radiology | Ausgabe 5/2009

Einloggen, um Zugang zu erhalten

Abstract

There is little published long-term survival data for patients with colorectal liver metastases treated with radiofrequency ablation (RFA). We present a multivariate analysis of 5-year survival in 309 patients (198 male, aged 64 (24–92)) treated at 617 sessions. Our standard protocol used internally cooled electrodes introduced percutaneously under combined US and CT guidance/monitoring. The number and size of liver metastases, the presence and location of extrahepatic disease, primary resection, clinical, chemotherapy and follow-up data were recorded. Data analysis was performed using SPSS v.10. On multivariate analysis, significant survival factors were the presence of extrahepatic disease (p < 0.001) and liver tumour volume (p = 0.001). For 123 patients with five or less metastases of 5 cm or less maximum diameter and no extrahepatic disease median survival was 46 and 36 months from liver metastasis diagnosis and ablation, respectively; corresponding 3- and 5-year survival rates were 63%, 34% and 49%, 24%. Sixty-nine patients had three or less tumours of below 3.5 cm in diameter and their 5-year survival from ablation was 33%. There were 23/617(3.7%) local complications requiring intervention. Five-year survival of 24–33% post ablation in selected patients is superior to any published chemotherapy data and approaches the results of liver resection.
Literatur
1.
Zurück zum Zitat Steward BW, Kleihues P (eds) (2003) Colorectal cancer. World cancer report. IACR, Lyon, pp 198–202 Steward BW, Kleihues P (eds) (2003) Colorectal cancer. World cancer report. IACR, Lyon, pp 198–202
2.
Zurück zum Zitat Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759–766PubMedCrossRef Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759–766PubMedCrossRef
3.
Zurück zum Zitat Kornprat P, Jarnagin WR, Gonen M, DeMatteo RP, Fong Y, Blumgart LH, D’Angelica M (2007) Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol 14:1151–1160PubMedCrossRef Kornprat P, Jarnagin WR, Gonen M, DeMatteo RP, Fong Y, Blumgart LH, D’Angelica M (2007) Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol 14:1151–1160PubMedCrossRef
4.
Zurück zum Zitat Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818–825PubMedCrossRef Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818–825PubMedCrossRef
5.
Zurück zum Zitat Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047PubMedCrossRef Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047PubMedCrossRef
6.
Zurück zum Zitat Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136–147PubMed Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136–147PubMed
7.
Zurück zum Zitat Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRef Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRef
8.
Zurück zum Zitat Cascinu S, Berardi R, Salvagni S, Beretta GD, Catalano V, Pucci F, Sobrero A, Tagliaferri P, Labianca R, Scartozzi M, Crocicchio F, Mari E, Ardizzoni A (2008) A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. Br J Cancer 98:71–76PubMedCrossRef Cascinu S, Berardi R, Salvagni S, Beretta GD, Catalano V, Pucci F, Sobrero A, Tagliaferri P, Labianca R, Scartozzi M, Crocicchio F, Mari E, Ardizzoni A (2008) A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. Br J Cancer 98:71–76PubMedCrossRef
9.
Zurück zum Zitat Gillams AR, Lees WR (2004) Radio-frequency ablation of colorectal liver metastases in 167 patients. Eur Radiol 14:2261–2267PubMedCrossRef Gillams AR, Lees WR (2004) Radio-frequency ablation of colorectal liver metastases in 167 patients. Eur Radiol 14:2261–2267PubMedCrossRef
10.
Zurück zum Zitat Gillams AR, Lees WR (2000) Survival after percutaneous, image-guided, thermal ablation of hepatic metastases from colorectal cancer. Dis Colon Rectum 43:656–661PubMedCrossRef Gillams AR, Lees WR (2000) Survival after percutaneous, image-guided, thermal ablation of hepatic metastases from colorectal cancer. Dis Colon Rectum 43:656–661PubMedCrossRef
11.
Zurück zum Zitat Vogl TJ, Mack MG, Roggan A, Straub R, Eichler KC, Muller PK, Knappe V, Felix R (1998) Internally cooled power laser for MR-guided interstitial laser-induced thermotherapy of liver lesions: initial clinical results. Radiology 209:381–385PubMed Vogl TJ, Mack MG, Roggan A, Straub R, Eichler KC, Muller PK, Knappe V, Felix R (1998) Internally cooled power laser for MR-guided interstitial laser-induced thermotherapy of liver lesions: initial clinical results. Radiology 209:381–385PubMed
12.
Zurück zum Zitat Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd GD III, Dupuy DE, Gervais D, Gillams AR, Kane RA, Lee FT Jr, Livraghi T, McGahan J, Phillips DA, Rhim H, Silverman SG (2005) Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology 235:728–739PubMedCrossRef Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd GD III, Dupuy DE, Gervais D, Gillams AR, Kane RA, Lee FT Jr, Livraghi T, McGahan J, Phillips DA, Rhim H, Silverman SG (2005) Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology 235:728–739PubMedCrossRef
13.
Zurück zum Zitat Jakobs TF, Hoffmann RT, Trumm C, Reiser MF, Helmberger TK (2006) Radiofrequency ablation of colorectal liver metastases: mid-term results in 68 patients. Anticancer Res 26:671–680PubMed Jakobs TF, Hoffmann RT, Trumm C, Reiser MF, Helmberger TK (2006) Radiofrequency ablation of colorectal liver metastases: mid-term results in 68 patients. Anticancer Res 26:671–680PubMed
14.
Zurück zum Zitat Solbiati L, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, Cova L, Halpern EF, Gazelle GS (2001) Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 221:159–166PubMedCrossRef Solbiati L, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, Cova L, Halpern EF, Gazelle GS (2001) Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 221:159–166PubMedCrossRef
15.
Zurück zum Zitat Sorensen SM, Mortensen FV, Nielsen DT (2007) Radiofrequency ablation of colorectal liver metastases: long-term survival. Acta Radiol 48:253–258PubMedCrossRef Sorensen SM, Mortensen FV, Nielsen DT (2007) Radiofrequency ablation of colorectal liver metastases: long-term survival. Acta Radiol 48:253–258PubMedCrossRef
16.
Zurück zum Zitat Aloia TA, Vauthey JN, Loyer EM, Ribero D, Pawlik TM, Wei SH, Curley SA, Zorzi D, Abdalla EK (2006) Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 141:460–466PubMedCrossRef Aloia TA, Vauthey JN, Loyer EM, Ribero D, Pawlik TM, Wei SH, Curley SA, Zorzi D, Abdalla EK (2006) Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 141:460–466PubMedCrossRef
17.
Zurück zum Zitat Abitabile P, Hartl U, Lange J, Maurer CA (2007) Radiofrequency ablation permits an effective treatment for colorectal liver metastasis. Eur J Surg Oncol 33:67–71PubMed Abitabile P, Hartl U, Lange J, Maurer CA (2007) Radiofrequency ablation permits an effective treatment for colorectal liver metastasis. Eur J Surg Oncol 33:67–71PubMed
18.
Zurück zum Zitat Siperstein AE, Berber E, Ballem N, Parikh RT (2007) Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 246:559–565PubMedCrossRef Siperstein AE, Berber E, Ballem N, Parikh RT (2007) Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 246:559–565PubMedCrossRef
19.
Zurück zum Zitat Machi J, Oishi AJ, Sumida K, Sakamoto K, Furumoto NL, Oishi RH, Kylstra JW (2006) Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and effectiveness in first- and second-line management. Cancer J 12:318–326PubMedCrossRef Machi J, Oishi AJ, Sumida K, Sakamoto K, Furumoto NL, Oishi RH, Kylstra JW (2006) Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and effectiveness in first- and second-line management. Cancer J 12:318–326PubMedCrossRef
20.
Zurück zum Zitat Elias D, Ouellet JF, Bellon N, Pignon JP, Pocard M, Lasser P (2003) Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Br J Surg 90:567–574PubMedCrossRef Elias D, Ouellet JF, Bellon N, Pignon JP, Pocard M, Lasser P (2003) Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Br J Surg 90:567–574PubMedCrossRef
21.
Zurück zum Zitat Yamada H, Kondo S, Okushiba S, Morikawa T, Katoh H (2001) Analysis of predictive factors for recurrence after hepatectomy for colorectal liver metastases. World J Surg 25:1129–1133PubMed Yamada H, Kondo S, Okushiba S, Morikawa T, Katoh H (2001) Analysis of predictive factors for recurrence after hepatectomy for colorectal liver metastases. World J Surg 25:1129–1133PubMed
22.
Zurück zum Zitat Bakalakos EA, Kim JA, Young DC, Martin EW Jr (1998) Determinants of survival following hepatic resection for metastatic colorectal cancer. World J Surg 22:399–404PubMedCrossRef Bakalakos EA, Kim JA, Young DC, Martin EW Jr (1998) Determinants of survival following hepatic resection for metastatic colorectal cancer. World J Surg 22:399–404PubMedCrossRef
23.
Zurück zum Zitat Wanebo HJ, Chu QD, Vezeridis MP, Soderberg C (1996) Patient selection for hepatic resection of colorectal metastases. Arch Surg 131:322–329PubMed Wanebo HJ, Chu QD, Vezeridis MP, Soderberg C (1996) Patient selection for hepatic resection of colorectal metastases. Arch Surg 131:322–329PubMed
24.
Zurück zum Zitat Ahmed M, Goldberg SN (2004) Combination radiofrequency thermal ablation and adjuvant IV liposomal doxorubicin increases tissue coagulation and intratumoural drug accumulation. Int J Hyperthermia 20:781–802PubMedCrossRef Ahmed M, Goldberg SN (2004) Combination radiofrequency thermal ablation and adjuvant IV liposomal doxorubicin increases tissue coagulation and intratumoural drug accumulation. Int J Hyperthermia 20:781–802PubMedCrossRef
Metadaten
Titel
Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation
Publikationsdatum
01.05.2009
Erschienen in
European Radiology / Ausgabe 5/2009
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-008-1258-5

Weitere Artikel der Ausgabe 5/2009

European Radiology 5/2009 Zur Ausgabe

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

13.04.2024 Klinik aktuell Kongressbericht

Die Teilnehmer eines Forums beim DGIM-Kongress waren sich einig: Fehler in der Medizin sind häufig in ungeeigneten Prozessen und mangelnder Kommunikation begründet. Gespräche mit Patienten und im Team können helfen.

Wie toxische Männlichkeit der Gesundheit von Männern schadet

08.04.2024 Andrologie Nachrichten

Stark, erfolgreich, allzeit belastbar – das sind Erwartungen, die Jungen und Männer von der Gesellschaft spüren. Das kann sie „toxisch“ werden lassen – und letztlich sogar der Gesundheit schaden, mahnt Dr. Dirk Sander von der Deutschen Aidshilfe.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.